Evaluation of the diurnal variation in the pharmacokinetics of zileuton in healthy volunteers.
The diurnal variation in the pharmacokinetic parameters of zileuton were evaluated in 12 healthy male volunteers in a three-period study. Periods I and II constituted a balanced, randomized, crossover study in which a participant received a single dose of 600-mg zileuton either at 7 AM or 11 PM. In period III all participants received 600-mg doses four times daily for 5 days. The differences between the pharmacokinetics of single doses of zileuton administered at 7 AM and 11 PM were not statistically significant. Plasma concentration-time profiles of zileuton during the four daily dose intervals at steady state were also similar. Values for the pharmacokinetic parameters of zileuton after multiple doses were similar to those after single doses, with a minimal accumulation of the drug after multiple doses. Overall, there was little or no diurnal variation in the pharmacokinetic parameters of zileuton after single and multiple doses.
Awni
W M
WM
Abbott Laboratories, Chicago, Illinois, USA.
Locke
C
C
Dube
L M
LM
Cavanaugh
J H
JH
D000293:Adolescent; D000328:Adult; D002940:Circadian Rhythm; D018592:Cross-Over Studies; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D016859:Lipoxygenase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D014508:Urea / Q000031:analogs & derivatives / Q000097:blood / Q000493:pharmacokinetics
D016859:Lipoxygenase Inhibitors; C097393:N-dehydroxyzileuton; D014508:Urea; C063449:zileuton; D006918:Hydroxyurea